OCT Medical Imaging Inc. Receives fast-track SBIR funding for “Clinical evaluation and development of a diagnostic multi-modal intravascular imaging system
Dr. Ram Ramalingam CEO of OCT Medical Imaging Inc. (OCTMI), a privately held medical device company announced that it has received a fast-tract Small Business Innovation Research (SBIR) grant from National Heart Lung Blood institute (NHLBI) for “Clinical evaluation and development of a diagnostic multi-modal intravascular imaging system”. This fast-track SBIR grant worth 2.9 million dollar with potential support for two and half-year will be led by Dr. Ram Ramalingam, Co-founder of OCTMI and will involve clinicians from Columbia University Medical School (CUMS) and University of California Irvine Medical School (UCIMS), Orange, California. This milestone based grant will be released in two phases, first phase involves pre-clinical and animal study and the second phase involves optimization and clinical study at CUMS and UCIMS. OCTMI propose to develop a cost-effective clinical multimodal intravascular imaging system that combines two FDA approved intravascular imaging technologies, ultra high-resolution optical coherence tomography (OCT) and Intravascular Ultrasound (IVUS) into a single catheter. This combined multimodal vascular imaging system will permit cross-sectional simultaneous real-time visualization deep into vascular artery wall at high resolution, not possible with any of these technologies alone. OCTMI proposes a cost-effective hybrid mini sensor that combines high spatial resolution of OCT and broad imaging depth of IVUS. According to Dr. Ram Ramalingam, this hybrid sensor based catheter ($850-$1200) could potentially replace separate ($600-$1000) catheter for each modality. Interventionists at their own discretion can now perform either IVUS-OCT multimodal imaging or “ IVUS” or “OCT” alone imaging during PCI procedures. Most importantly hybrid-imaging sensor can not only reduce entire procedure time but also could reduce hospital cost upto 50% with better outcomes and less exposure to toxic contrast agents, benefitting patients as well. According to Dr. Ramalingam, these studies will broaden the use of IVUS-OCT platform technology to intravascular imaging not only to detect vulnerable plaques during PCI interventions, but also its utility in, vessel sizing, stent sizing and post stent follow-up and have potential application in perivascular and carotid artery disease.